Drugs / GAA/TT-peptide vaccine
last change Jul 2015 re-read 2 minutes ago

GAA/TT-peptide vaccine

Vaccine

Developed for
low-grade astrocytoma · oligoastrocytoma
Investigated by
Ian F. Pollack, M.D. · National Cancer Institute (NCI) · Oncovir, Inc.

Trials 1 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT00795457 Jan 2009 → Feb 2013 low-grade astrocytoma, oligoastrocytoma Ian F. Pollack, M.D. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GAA/TT-peptide vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00795457
Modality Vaccine “This is a pilot vaccine study in adults with either WHO grade II astrocytoma, oligoastrocytoma or oligodendroglioma.” NCT00795457
Route Subcutaneous subcutaneous injections of GAA/TT-vaccines” NCT00795457